



July 2, 2012
AnGes MG, Inc.

Mitsubishi Tanabe Pharma and AnGes Conclude Basic Agreement for Exclusive Marketing Rights of Collategene[®] in the United States

AnGes MG, Inc. ("AnGes") announced today that it has concluded a basic agreement with Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, President & CEO: Michihiro Tsuchiya, "MTPC") for the exclusive marketing rights of Collategene[®] (DNA Plasmid with HGF gene) as a treatment for Peripheral Arterial Disease (PAD) in the United States.

AnGes has been seeking for a partner to pursue the global Phase III study regarding Collategene[®] as a treatment for Critical Limb Ischemia (CLI), the severe stage of arteriosclerosis obliterans and Buerger's disease. AnGes is pleased to announce that it has reached the basic agreement regarding the exclusive marketing rights as stated above. Once the contract regarding the exclusive marketing rights is concluded, AnGes will receive upfront payments and milestone payments. AnGes believes that it can maximize the asset value of Collategene[®] by conducting a prompt global Phase III study centered in the United States which has the biggest market in the world.

Ei Yamada, President and CEO of AnGes commented, "It is estimated that there are more than 5 hundred thousand patients with CLI in the United States alone, with a market size estimated at 5 billion US dollars. For the global development of Collategene[®], it is crucial to proceed with the development in the United States, which has the main market for Collategene[®]. AnGes through its US subsidiary AnGes, Inc. has been conducting discussions with the Food and Drug Administration (FDA) and has already reached agreement on SPA (Special Protocol Assessment) for the Phase III global clinical study as well as obtaining Fast Track Drug Development Program which is designed to facilitate the development and expedite the review of new drugs. We aim to obtain the marketing approval at an early date by promptly advancing the development of this project."

AnGes will continue to take proactive steps for the development of Collategene[®] to provide a new treatment option for patients with CLI.

The effect of this event on AnGes's business performance for the fiscal term ending in December 2012 is currently under calculation, and it will be published as soon as the result becomes clear.

###

About Collatogene[®]: The Characteristics and Medical Significance

HGF (Hepatocyte Growth Factor) is known to have a strong angiogenic activity. HGF Plasmid is a regenerative medicine that is used to improve ischemic condition by administrating HGF producing gene to the location of ischemia which leads to angiogenesis by HGF protein produced in the administrated area. This drug is naked plasmid DNA, meaning it does not use virus vector thus it can prevent the adverse effects caused by a virus vector. It is different from the existing drugs which are symptomatic treatment, and improves ischemic condition by angiogenesis. Thus it is expected to become an innovative treatment medicine that is effective to intractable PAD which cannot be treated by the existing drugs.

AnGesMG, Inc.

Corporate Communications

TEL:+81-3-5730-2480, FAX:+81-3-5730-2676

<http://www.anges-mg.com>

Email:info@anges-mg.com